We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Insilico Medicine

Insilico Medicine, a clinical stage biotech company powered by generative artificial intelligence (AI), is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties.

Latest Content

Silhouette of woman practicing yoga pose at sunset by the water, promoting wellness and balance.

AI Collaboration Targets Women’s Health Diseases

AI-based tools analyze complex biological data to identify high-potential drug targets, supporting faster development of therapies for gynecological diseases.

Computer coding text over a virtual image of a human face.

AI Aids Drug Discovery for Lyosomal Storage Disease

Artificial intelligence is becoming increasingly important in drug discovery. Advances in the use of Big Data, learning algorithms and powerful computers have now enabled researchers to better understand a serious metabolic disease.

Black and white photograph of two hands.

Gray Hair and Wrinkles at an Early Age Led to New Treatment for a Rare Cancer

Researchers have found a way to predict which patients with sarcoma – a rare cancer of the bones and muscles – will benefit the most from a potential new treatment.

Accelerating Efficient Drug Discovery With the Power of AI content piece image

Industry Insight

Accelerating Efficient Drug Discovery With the Power of AI

To find out more about how generative artificial intelligence (AI) is helping to accelerate and advance drug discovery processes, we spoke to Dr. Alex Zhavoronkov, CEO of Insilico Medicine.

Insilico Medicine Receives FDA Orphan Drug Designation for INS018_055

Insilico Medicine has announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to INS018_055 for the treatment of idiopathic pulmonary fibrosis.

Two of the study's authors standing together in a robotics laboratory.

AlphaFold and AI Accelerate Design of New Liver Cancer Drug

A new study has successfully used AlphaFold, an artificial intelligence (AI)-powered protein structure database, to accelerate the design and synthesis of a drug to treat the most common type of primary liver cancer.

Research Collaboration Yields New Treatment Possibilities for ALS content piece image

Industry Insight

Research Collaboration Yields New Treatment Possibilities for ALS

Frank Pun discusses how scientists from Insilico Medicine identified numerous unreported potential therapeutic targets of amyotrophic lateral sclerosis using the company’s proprietary AI-enabled biological target discovery platform.

The Impact of Funding on Longevity Research content piece image

Industry Insight

The Impact of Funding on Longevity Research

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter